For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Fri, 08/01/2014 to Wed, 08/01/2018
Bone Marrow Disease(s):
myelodysplastic syndromes (MDS)
Drug: MEK 162 Phase I Starting Dose of MEK 162: 15 mg by mouth twice a day in a 28 day cycle. Phase II Starting Dose of MEK 162: Maximum tolerated dose from Phase I.